1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Calliditas Therapeutics AB (publ)
  6. Summary
    CALTX   SE0010441584

CALLIDITAS THERAPEUTICS AB (PUBL)

(CALTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/13/2022 05/16/2022 05/17/2022 05/18/2022 05/19/2022 Date
69.85(c) 73.3(c) 74.05(c) 79.6(c) 88 Last
118 175 226 331 308 952 667 549 415 703 Volume
+3.48% +4.94% +1.02% +7.49% +10.55% Change
More quotes
Estimated financial data (e)
Sales 2022 540 M 54,0 M 54,0 M
Net income 2022 -595 M -59,5 M -59,5 M
Net cash position 2022 6,81 M 0,68 M 0,68 M
P/E ratio 2022 -7,44x
Yield 2022 -
Sales 2023 1 962 M 196 M 196 M
Net income 2023 528 M 52,7 M 52,7 M
Net cash position 2023 23,5 M 2,35 M 2,35 M
P/E ratio 2023 52,5x
Yield 2023 -
Capitalization 4 233 M 423 M 423 M
EV / Sales 2022 7,82x
EV / Sales 2023 2,15x
Nbr of Employees 86
Free-Float 82,0%
More Financials
Company
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug... 
Sector
Pharmaceuticals
Calendar
05/19Shareholder meeting
More about the company
Ratings of Calliditas Therapeutics AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CALLIDITAS THERAPEUTICS AB (PUBL)
05/18Calliditas Therapeutics - First patient randomized in Phase 2 trial in head and neck ca..
AQ
05/18Calliditas - Interim Report Q1, 2022
AQ
05/18TRANSCRIPT : Calliditas Therapeutics AB, Q1 2022 Earnings Call, May 18, 2022
CI
05/18Interim Report Q1, 2022
AQ
05/18Calliditas Therapeutics AB Reports Earnings Results for the First Quarter Ended March 3..
CI
05/17Calliditas Therapeutics Starts Enrollment of Mid-Stage Head and Neck Cancer Study
MT
05/17Calliditas Says First Patient Randomized in Mid-Stage Head and Neck Cancer Trial
MT
05/17First patient randomized in Phase 2 trial in head and neck cancer
AQ
05/17Calliditas Therapeutics AB Announces First Patient Randomized in Phase 2 Trial in Head ..
CI
05/16European ADRs Move Higher in Monday Trading
MT
05/14Calliditas Therapeutics Launches an Online Patient Platform
AQ
05/14Calliditas Therapeutics AB Launches an Online Patient Platform
CI
05/10Calliditas Therapeutics to participate in upcoming investor conferences
AQ
05/02Number of shares and votes in Calliditas Therapeutics
AQ
04/29Number of shares and votes in Calliditas Therapeutics
AQ
More news
News in other languages on CALLIDITAS THERAPEUTICS AB (PUBL)
05/18Calliditas Therapeutics AB (publ) annonce ses résultats pour le premier trimestre clos ..
05/17Calliditas Therapeutics commence le recrutement d'une étude de stade intermédiaire sur ..
05/17Calliditas Therapeutics AB (Publ) annonce la randomisation du premier patient dans un e..
05/16Les ADR européens progressent lundi
05/16BOLSA DE MADRID : Aterrizaje brusco en China
More news
Analyst Recommendations on CALLIDITAS THERAPEUTICS AB (PUBL)
More recommendations
Chart CALLIDITAS THERAPEUTICS AB (PUBL)
Duration : Period :
Calliditas Therapeutics AB (publ) Technical Analysis Chart | CALTX | SE0010441584 | MarketScreener
Technical analysis trends CALLIDITAS THERAPEUTICS AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 79,60 SEK
Average target price 202,50 SEK
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Renée Julie Elisabet Aguiar-Lucander Chief Executive Officer
Fredrik Johansson Chief Financial Officer
Elmar J. Schnee Chairman
Johan Erik Häggblad Chief Scientific Officer
Richard Philipson Chief Medical Officer
Sector and Competitors